A Phase II Single-arm Study of Tazemetostat With Docetaxel, Cisplatin, and 5-fluorouracil as Preoperative Treatment for Locally Advanced Potentially Resectable SMARCB1 (INI-1)- Deficient Sinonasal Carcinoma
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary) ; Tazemetostat (Primary)
- Indications Carcinoma; Head and neck cancer; Nasopharyngeal cancer
- Focus Therapeutic Use
- 26 Feb 2023 Planned initiation date changed from 1 Sep 2022 to 1 Sep 2023.
- 15 Dec 2021 New trial record